EANS-Adhoc

Marinomed Biotech AG / Sellers complete accelerated bookbuilding; 105,000 Marinomed shares have been sold for EUR 95 per share - Seite 2

Biotech AG's share capital. The upsize alternative of up to 50,000 additional
Marinomed shares was fully exercised.

The Marinomed shares are sold for EUR 95.00 each. The total sale proceeds of the
ABB for Acropora, VETWIDI and BVT therefore amounts to approximately EUR 10
million. Settlement of Marinomed shares placed in the ABB is scheduled for 27
January 2020.

Erste Group Bank AG acted as the sole bookrunner.

Following completion of the ABB, Acropora, VETWIDI and BVT still hold
approximately 16.6 per cent. (Acropora), approximately 1.5 per cent. (VETWIDI)
and approximately 1.4 per cent. (BVT) of the share capital of Marinomed Biotech
AG. For these shares the lock-up commitment entered into the course of the ABB
applies for a period of 90 days.

About Marinomed Biotech AG
Marinomed Biotech AG is a biopharmaceutical company with headquarters in Vienna
and has been listed in the Prime Market of the Vienna Stock Exchange since
February 1, 2019. The company focuses on the development of innovative products
based on patent-protected technology platforms in the field of respiratory and
ophthalmological diseases. The Marinosolv® technology platform increases the
efficacy of hardly soluble compounds for the treatment of sensitive tissues such
as the eyes and nose. The Carragelose® platform comprises innovative patent-
protected products targeting viral infections of the respiratory tract.
Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold
via international partners in over 40 countries worldwide. Further information
is available at: www.marinomed.com [http://www.marinomed.com/].

Disclaimer
This announcement constitutes neither an offer to buy securities nor a
solicitation of an offer to buy securities in the United States of America,
Germany, Austria or other countries. The securities are not sold or offered to
be sold in the United States of America under the rules of the US Securities Act
of 1933, as amended. The shares have already been placed.

A public offer of the securities was neither made in Austria nor in any other
jurisdiction. Any offer of shares under the ABB was made solely on the basis of
an exemption from the obligation to publish a prospectus in accordance with
Article 1 (4) of Regulation (EU) 2017/1129 of the European Parliament and of the
Council of 14 June 2017 (the "Prospectus Regulation") and was exclusively
intended for qualified investors within the meaning of Article 2 (e) of the
Prospectus Regulation."




Further inquiry note:
Pascal Schmidt
Chief Financial Officer, Marinomed
Veterinärplatz 1, 1210 Vienna, Österreich
T [phone]
E-Mail: [e-mail]
http://www.marinomed.com

Roland Mayrl
Managing Partner, Metrum Communications
Bauernmarkt 10/19, 1010 Vienna, Austria
T [phone]
E-Mail: [e-mail]
http://www.metrum.at





end of announcement euro adhoc
--------------------------------------------------------------------------------





issuer: Marinomed Biotech AG
Veterinärplatz 1
A-1210 Wien
phone: [phone]
FAX: [phone]
mail: [e-mail]
WWW: www.marinomed.com
ISIN: ATMARINOMED6, AT0000A1WD52
indexes:
stockmarkets: Wien
language: English


Additional content: https://www.presseportal.de/pm/132651/4499795
OTS: Marinomed Biotech AG